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REPLY
We thank Dr. Cheng for his interest in our work (1) and
appreciate his comments. The prevalence of hypertrophic cardio-
myopathy (HCM) appears similar among different racial groups.
Population studies comprising more than 16,000 subjects from
Japan, China, and the U.S. (Caucasian, African, and native
Americans) have established that unexplained left ventricular (LV)
wall thickness 15 mm occurs with a prevalence of about 0.2%
(range 0.16% to 0.23%) (2–5). Recent genotype–phenotype studies
have revealed that the disease expression of HCM is extremely
heterogeneous and that many gene carriers present with electro-
cardiographic (ECG) abnormalities in the absence of LV hyper-
trophy on echocardiography. It is likely, therefore, that the true
prevalence of HCM is well above 0.2% (1). Furthermore, the
prevalence of HCM appeared to be similar in each of the screening
studies despite considerable age differences in the study popula-
tions, which suggests that HCM may develop independent of age.
This finding is in contrast to previous assumptions that HCM
develops during adolescence and early adulthood. If this was the
case, the prevalence would be age-dependent and expected to be
high at young ages and low at older ages owing to increased
mortality rates associated with HCM. Apparently, the number of
individuals dying equals the number of individuals developing the
condition at any age, resulting in a “steady-state” and age-
independent prevalence of the condition.
The frequency of mutations in the gene for cardiac troponin I
(TNNI3) has been reported in six larger studies (6–9). A total of
1,697 HCM patients have been investigated (range: 71 to 748
patients), with an average frequency of TNNI3 mutations of 2.7%
(range 0.9% to 4.0%). The studies were conducted in patients in
Great Britain, the U.S., France, China, Japan, Korea, and Ger-
many. The modest differences in frequency of mutations are most
likely explained by differences in sample sizes of patients and do
not appear to be associated with race.
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Impact of Carvedilol Before
Angiotensin-Converting Enzyme
Inhibitor Therapy on Cardiac Function
The study by Sliwa et al. (1) is indeed an eye-opener for those who
depend on expert opinions such as those from the American
College of Cardiology/American Heart Association guidelines
(1,2). However, despite a well-executed study, I am not sure the
conclusions drawn by the editor and investigators are entirely on
the mark. My main criticism is that this is a “how-to” treat and not
a “what to” treat study, and as a result it cannot ignore practicality
issues. In clinical practice, how often do we see 78 consecutive
newly diagnosed patients with New York Heart Association
(NYHA) functional classification II to IV go directly to oral
anticongestive therapy without the need for parenteral vasodilator
intervention initially? In these patients, is it really practical to
switch directly from parenteral therapy to oral beta-blockade
without the support of an afterload reducing agent? Even among
specialists, a measurable dropout rate would be expected if every
patient went straight to a beta-blocker. In fact, the concept of
using an inodilator to facilitate the commencement of a beta-
blocker in those patients who would otherwise not tolerate
adrenaline withdrawal or inhibition is for this very reason.
Conversely, concerning the control arm, are there many prac-
titioners who would wait six months before introducing a beta-
blocker? Therefore, I am surprised the researchers did not elabo-
rate on the treatment status of the subjects before they were
randomized to the carvedilol arm, and whether they encountered
difficulties during up-titration. Furthermore, as a significant num-
ber of subjects expired during the study (11 of 78, 14% after 12
months), how many required readmission for decompensation and
what happened to their beta-blocker dosing regimen?
As for the results, improved biochemical profile, NYHA func-
tional class, and echocardiographic function in the carvedilol-
initiated group would indicate that carvedilol is a more “potent”
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